DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain

CUPERTINO, Calif., Oct. 2, 2019 -- (Healthcare Sales & Marketing Network) -- DURECT Corporation (Nasdaq: DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bu... Biopharmaceuticals, Drug Delivery, Surgery, FDA DURECT, POSIMIR, bupivacaine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news